Search results

Federal Parliament’s House Standing Committee on the Environment and Energy has presented its report, arising from its Inquiry into the prerequisites for nuclear energy in Australia today.

ANSTO has been granted a patent in Australia and a number of European countries for the separation, a key radioactive contaminant in critical minerals processing, actinium-227, from process liquors used in minerals extraction.

Recognition of research that developed a life-saving pharmaceutical milkshake using synchrotron techniques.

Two early career nuclear scientists who received international scholarships have spent time in the Nuclear Fuel Cycle group at ANSTO are making progress on their work to improve nuclear fuel.

Elastic Recoil Detection Analysis (ERDA) is used principally as a method for measuring hydrogen in thin layers, and in the near-surface region of materials.

ANSTO is interested finding students to collaborate on Generation IV reactor systems.

This joint initiative at ANSTO has developed a new capability: solid surface radiolabelling to evaluate Auger emitting sources for next-generation targeted therapy.

ANSTO recognised the contribution of individuals and teams to nuclear science and technology at the 2023 ANSTO Awards Ceremony held on 25 July.

Following your experiment at ANSTO there are certain tasks that users can complete including a user feedback survey and claiming reimbursement for travel expenses.

You are invited to submit to the various awards from ANSTO, User Advisory Committee (UAC) and Australian Neutron Beam User Group (ANBUG). 

A team of Melbourne researchers and international partners from Italian Instituto Nazionale de Fisica Nucleare (INFN) and CERN, who are developing radiation-hardened semiconductor chips, used the unique state-of-art high energy ion microprobe on the SIRIUS ion accelerator at ANSTO’s Centre for Accelerator Science to test a prototype radiation-resistant computer chip

The Macromolecular Crystallography beamlines at the Australian Synchrotron (MX1 and MX2) are general purpose crystallography instruments for determining chemical and biological structures.

Phase contrast tomography shows great promise in early stages of study and is expected to be tested on first patients by 2020.